AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

The secrets of idiopathic pulmonary fibrosis (IPF) are written in its very name. Idiopathic refers to a disease of unknown ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 ...

Kassandra Klemenz has pushed through challenges her entire life. Today, she uses that endurance to compete in triathlons.

As immunotherapy becomes a cornerstone of cancer treatment, some of the top U.S. cancer centers and health systems are accelerating research efforts to identify the biological mechanisms behind ...

Scientists uncover surprising immune response that helps tumors grow, revealing new strategies to improve treatment ...